Sanofi to go public with clinical trial data, supporting data sharing and EHR
Written by Alyssa Clark
Following suit with other large pharma companies, Sanofi has jumped onto the data sharing bandwagon— the corporation has recently stated that it plans to release clinical trial data in an effort to enable a website where researchers can easily and readily request study information. First pioneered by GlaxoSmithKline last year, it seems as if this recent trend to support research and data sharing is a suit for everyone to follow in the upcoming year. Whether the gesture will satisfy industry critics remains to be seen. Sanofi will make available trial data and related documents, including clinical study reports, for studies in human that were submitted to US and European regulators and the product must have been approved by both agencies – on or after January 1, 2014.
Industry trade groups in the US and Europe have pushed for this decision for quite some time now, with their proposed plans of data sharing which are currently being considered by the European Medicines Agency. Critics have generated a lot of discussion concerning the past lack of access to research data and statistics from corresponding studies, and whether or not Sanofi’s move to join the new wave of sharing-friendly pharma companies will satisfy public uneasiness is still too new to determine.
“Finding new therapies can be accelerated by fully sharing the successful and unsuccessful research results with other researchers. Data sharing helps to reduce duplication and allows researchers to build more effectively on the findings of other researchers,” says Sanofi ceo Chris Viehbacher, who is also president of the European Federation of Pharmaceutical Industries and Associations, in a statement.
This new public information will silence the long-standing criticism of the credibility of the statistics generated by pharma giants in terms of how they market their products and the consequential success of the specific product. Drugmakers’ excuse of clinical trial data being “proprietary” has officially run out in the public’s opinion, and now forcing companies to be responsible for the raw numbers of their respective drugs will hopefully reinstate some truth to an industry long-buried in dirty money secrets. After seeing scandals like Glaxo and Johnson & Johnson, in which the companies were cited nearly $3 billion in settlements for withholding information about side effects, the demand for honest and reliable numbers is at an all-time-high.
For the most part, drugmakers have resisted any change, although since Glaxo launched its web site to provide patient-level data to researchers, upon request, several others have now agreed to participate, including Roche, Boerhinger Ingelheim, ViiV Healthcare – a joint venture between Glaxo, Pfizer and Shionogi to develop HIV medicines.
Though impossible to predict the future behaviors of the pharma industry, bringing clinical trial data to the public eye is a small victory for the everyday patient and those researchers working on behalf of public health to provide us with the truth about the healthcare that’s available to us.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”